Literature DB >> 18523733

Clinical pharmacology of gold.

W F Kean1, I R L Kean.   

Abstract

Since the dawn of civilization, elemental gold and gold compounds have been revered and utilized by Shamen and medical practitioners alike for many varied pathological problems. In the 20(th) century following the observations of Jacques Forestier, injectable gold compounds were successfully used for the treatment of rheumatoid arthritis. Of the many compounds developed, gold sodium thiomalate has been the most extensively studied by basic scientists and by clinicians. In the1980s, the oral gold compound auranofin showed promise as a therapeutic contender to injectable gold, but the clinical side effect profile and fear of long term effects of immune suppression by auranofin, resulted in gold sodium thiomalate continuing as the preferred gold compound for rheumatoid treatment. However, the increased use and demonstration of effectiveness of low dose Methotrexate (MTX) in rheumatoid treatment over the last 20 years has resulted in a significant decline in the use of injectable gold sodium thiomalate, this despite the claims and evidence that it remains a useful agent in the management of rheumatoid arthritis. Several authors still contend that the injectable gold compounds can still play a valuable role, and indeed may be the correct first choice in the management of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523733     DOI: 10.1007/s10787-007-0021-x

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  41 in total

1.  Assessment of exposures and potential risks to the US adult population from wear (attrition and abrasion) of gold and ceramic dental restorations.

Authors:  G Mark Richardson; Scott R Clemow; Rachel E Peters; Kyle J James; Steven D Siciliano
Journal:  J Expo Sci Environ Epidemiol       Date:  2015-03-25       Impact factor: 5.563

2.  Our silver jubilee/anniversary 1991-2016.

Authors:  Michael Whitehouse
Journal:  Inflammopharmacology       Date:  2016-12       Impact factor: 4.473

Review 3.  The biological activity of auranofin: implications for novel treatment of diseases.

Authors:  J M Madeira; D L Gibson; W F Kean; A Klegeris
Journal:  Inflammopharmacology       Date:  2012-09-11       Impact factor: 4.473

4.  Effect of quality-switched laser exposure in patients with history of edible gold consumption.

Authors:  Abdullah AlHargan; Saad AlTalhab; Yasser Ghobara; Ahmed Alissa; Mohammed I AlJasser
Journal:  Lasers Med Sci       Date:  2019-04-03       Impact factor: 3.161

Review 5.  Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future.

Authors:  Rochelle R Arvizo; Sanjib Bhattacharyya; Rachel A Kudgus; Karuna Giri; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

6.  Titanates and Titanate-Metal Compounds in Biological Contexts.

Authors:  Yen-Wei Chen; Jeanie L Drury; Whasun Oh Chung; David T Hobbs; John C Wataha
Journal:  Int J Med Nano Res       Date:  2015-06-13

7.  Q-Switched Alexandrite Laser-induced Chrysiasis.

Authors:  Philip R Cohen; E Victor Ross
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

8.  Fatality from potassium gold cyanide poisoning.

Authors:  Elizabeth Harmon; Jacob Lebin; David Murphy; Bjorn Watsjold
Journal:  BMJ Case Rep       Date:  2019-07-26

9.  Intraoperative diagnostics and elimination of residual microtumours with plasmonic nanobubbles.

Authors:  Ekaterina Y Lukianova-Hleb; Yoo-Shin Kim; Ihor Belatsarkouski; Ann M Gillenwater; Brian E O'Neill; Dmitri O Lapotko
Journal:  Nat Nanotechnol       Date:  2016-02-15       Impact factor: 39.213

10.  A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia.

Authors:  Noa Tejman-Yarden; Yukiko Miyamoto; David Leitsch; Jennifer Santini; Anjan Debnath; Jiri Gut; James H McKerrow; Sharon L Reed; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.